Age of child.

No definition available.

Name:	dbvt_AgeOfChild
Namespace Prefix:	dbvt_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Clinical program trial period.

+ References

No definition available.

+ Details

Name:	dbvt_ClinicalProgramTrialPeriod
Namespace Prefix:	dbvt_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of additional candidates for which the study shall be conducted.

+ References

No definition available.

+ Details

Name:	dbvt_NumberOfAdditionalCandidatesForWhichTheStudyShallBeConducted
Namespace Prefix:	dbvt_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Period for which the study shall be carried out.

+ References

No definition available.

+ Details

Name:	dbvt_PeriodForWhichTheStudyShallBeCarriedOut
Namespace Prefix:	dbvt_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Total number of additional candidates covered by the study.

+ References

No definition available.

+ Details

Name:	dbvt_TotalNumberOfAdditionalCandidatesCoveredByTheStudy
Namespace Prefix:	dbvt_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The cash outflow for cost incurred directly with the issuance of an equity security.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-15

+ Details

Name:	us-gaap_PaymentsOfStockIssuanceCosts
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The cash inflow from the additional capital contribution to the entity.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 14
-Subparagraph (a)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-14

+ Details

Name:	us-gaap_ProceedsFromIssuanceOfCommonStock
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Cash received on stock transaction after deduction of issuance costs.

+ References

No definition available.

+ Details

Name:	us-gaap_SaleOfStockConsiderationReceivedOnTransaction
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Per share or per unit amount of equity securities issued.

+ References

No definition available.

+ Details

Name:	us-gaap_SharesIssuedPricePerShare
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-SubTopic 10
-Topic 505
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481004/946-505-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(i)(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-SubTopic 10
-Topic 505
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4

+ Details

Name:	us-gaap_StockholdersEquityNoteStockSplitConversionRatio1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:pureItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_StatementClassOfStockAxis=dbvt_AmericanDepositarySharesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=dbvt_ViaskintmClinicalProgramForChildrenAgedBetweenFourToElevenMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dbvt_ProgrammeAxis=dbvt_ComfortChildrenSafetyStudyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dbvt_ProgrammeAxis=dbvt_ComfortToddlersSafetyStudyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dbvt_ProgrammeAxis=dbvt_SeparateSixMonthSafetyStudyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Significant Events and Transactions of the Periods - Additional Information (Detail) $ / shares in Units, $ in Millions				1 Months Ended	6 Months Ended
	Jul. 31, 2023 Candidates	Dec. 31, 2022 Persons	Jan. 31, 2020	Jun. 30, 2023 USD ($) $ / shares shares	Jun. 30, 2023 USD ($) $ / shares	Jun. 30, 2023 € / shares
American Depositary Shares [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock Issued During Period, Shares, New Issues \| shares				2,052,450
Shares Issued, Price Per Share \| (per share)				$ 1.9	$ 1.9	€ 3.52
Stockholders' Equity Note, Stock Split, Conversion Ratio				1.0809
Proceeds From Issuance Of Common Stock				$ 7.8
Sale of stock net consideration received on the transaction					$ 6.9
Payment of stock issuance costs					$ 0.9
ViaskinTM Clinical Program For Children Aged Between Four to Eleven [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Clinical Program Trial Period			6 months
ViaskinTM Clinical Program For Children Aged Between Four to Eleven [Member] \| Comfort Children Safety Study [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Period for which the study shall be carried out	6 months
ViaskinTM Clinical Program For Children Aged Between Four to Eleven [Member] \| Comfort Toddlers Safety Study [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total number of additional candidates covered by the study \| Candidates	400
Period for which the study shall be carried out	6 months
ViaskinTM Clinical Program For Children Aged Between Four to Eleven [Member] \| Separate Six Month Safety Study [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total number of additional candidates covered by the study \| Persons		600
Number of additional candidates for which the study shall be conducted \| Persons		275
Period for which the study shall be carried out		6 months
Minimum [Member] \| ViaskinTM Clinical Program For Children Aged Between Four to Eleven [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Age Of Child			4 years
Minimum [Member] \| ViaskinTM Clinical Program For Children Aged Between Four to Eleven [Member] \| Comfort Children Safety Study [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Age Of Child	4 years
Minimum [Member] \| ViaskinTM Clinical Program For Children Aged Between Four to Eleven [Member] \| Comfort Toddlers Safety Study [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Age Of Child	1 year
Minimum [Member] \| ViaskinTM Clinical Program For Children Aged Between Four to Eleven [Member] \| Separate Six Month Safety Study [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Age Of Child		4 years
Maximum [Member] \| ViaskinTM Clinical Program For Children Aged Between Four to Eleven [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Age Of Child			11 years
Maximum [Member] \| ViaskinTM Clinical Program For Children Aged Between Four to Eleven [Member] \| Comfort Children Safety Study [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Age Of Child	7 years
Maximum [Member] \| ViaskinTM Clinical Program For Children Aged Between Four to Eleven [Member] \| Comfort Toddlers Safety Study [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Age Of Child	3 years
Maximum [Member] \| ViaskinTM Clinical Program For Children Aged Between Four to Eleven [Member] \| Separate Six Month Safety Study [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Age Of Child		7 years